ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Inspire Welcomes Jeff Trotter as Chief Science Officer

Arlington, VA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Inspire, the world’s largest online health community, today announced the appointment of Jeff Trotter as Chief Science Officer (CSO). With over 40 years of pioneering experience in health economics, outcomes research, and real-world evidence (RWE), Trotter brings unparalleled expertise to Inspire’s leadership team. He will support Inspire and its clients on a consulting basis, driving innovation and ensuring that patient-centric solutions are aligned with cutting-edge scientific strategy.

Trotter’s career spans the clinical development and commercialization landscape, having founded leading consultancies and served in executive roles at several prominent contract research organizations. A renowned expert in observational studies, patient registries, and real-world data (RWD), Trotter will leverage his extensive knowledge to enhance Inspire’s data-driven offerings for biopharma, medical device companies, and other life sciences sectors.

"We are thrilled to have Jeff join our team in this pivotal role," said Brett Kleger, CEO of Inspire. "His deep understanding of real-world evidence and his track record in research design and implementation will be invaluable as Inspire continues to grow. Jeff’s insights have already played a crucial role in the advancement of our RWE services, and his expanded role marks a significant milestone for our company as we enter a new phase of growth."

In addition to his advisory role with Inspire, Trotter will continue to lead J Trotter Research & Consulting, offering strategic guidance to a broader array of clients. His dual responsibilities will enable a unique cross-pollination of insights between Inspire’s cutting-edge patient-centric platform and his independent consultancy, benefiting all stakeholders involved.

“I’m excited to deepen my collaboration with Inspire at this transformative time,” said Trotter. “Inspire’s ability to tap into the voices and real-world experiences of its 10 million patients across diverse medical conditions is truly unmatched. I look forward to contributing to the company’s mission of bringing valuable insights to the life sciences industry and ultimately improving outcomes for patients, caregivers, and healthcare providers.”

Trotter will also serve on Inspire’s Advisory Board, providing strategic direction on future initiatives and ensuring that Inspire’s RWE solutions continue to meet the evolving needs of its clients while advancing patient care across the continuum of clinical development and commercialization. Join Inspire at the IMPACCT RWE Summit to learn more about how our patient-centric platform and real-world evidence solutions are driving innovation in the life sciences industry.

About Inspire 

Founded in 2005, Inspire is the leading health community, connecting over 10 million patients and caregivers across 3,000 disease areas. Through its robust patient-centric platform, Inspire supports initiatives across the clinical development lifecycle—from preclinical research to post-market access—enabling life sciences organizations to capture real-world insights and accelerate medical advancements.  For more information, visit www.inspire.com.

Attachment


Jillian Tygh
Inspire
267-254-3997
jillian.tygh@inspire.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.